FDA Inspection Finds Numerous Problems At Facility Intended To Make J&J Vaccine

Content Curator
The Emergent BioSolutions Bayview Campus plant in Baltimore has stopped producing vaccine material following an FDA inspection that found numerous problems. The plant was slated to become part of the Johnson & Johnson COVID-19 vaccine production process.

The report on Emergent BioSolutions' Baltimore factory found an array of problems, from peeling paint to inadequate measures to prevent cross-contamination. Manufacturing at the facility is on hold.

(Image credit: Tasos Katopodis/Getty Images)